Timberline Resources Corp (NYSEMKT:TLR) trades flat, Zogenix Inc. (NASDAQ:ZGNX)

Posted by Lynn Eisler May 13, 2013 0 Comment 909 views


Miami, FL 05/13/2013 (GDPInsider) – Timberline Resources Corp (NYSEMKT:TLR) is down by gaining 0.87% in today’s trading session and currently trading at $0.193, after starting its day with a value of $0.20. The share is trading down by about $0.002 from its previous close of $0.18 and ranged in between $0.18 and $0.20 throughout the day. At a price of $0.195 and 62.27 million shares the total value of the company is more than $12.14 million. The earnings per share of the company is -$0.12. The 52-week trading range of the stock is $0.13 and $0.50. At the current levels the stock is trading above the 50 days MA of $0.17 but below its 200 days MA of $0.28. The RSI of the stock is 59.93.

The company reported its 1Q2013 results where, where it reported a lower loss from continuing operations of about $653 million in the current quarter as compared to a loss of $1100 million in the per share. The consolidated net loss per share stood at -$0.01 as compared to a net loss per share of -$0.02 a year ago.

Is TLR a solid investment at these levels? Get valuable updates and exclusive insights here.

Zogenix, Inc. (NASDAQ:ZGNX) is down by gaining 1.05% in today’s trading session and currently trading at $1.77, after starting its day with a value of $1.83. The share down by about $0.02 from its previous close of $1.66 and ranged in between $1.64 and $1.83. At a price of $1.77 and 0.328 million shares the total value of the company is more than $180.45 million. The earnings per share of the company is -$0.64. The 52-week trading range of the stock is $1.11 and $3.30. At the current levels the stock is trading above the 50 days MA of $1.75 but below its 200 days MA of $2.00. The RSI of the stock is 59.37.

The company announced that the Food and Drug Administration has informed the company that it would reach a conclusion on it drug Zohydro a powerful new painkiller, until this summer.

How Should Investors Trade ZGNX Now? Get the latest trends and data here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Lynn Eisler

Lynn Eisler is a national news reporter focusing on economic issues, data analysis and the financial health of state and local governments. Lynn has been honored with the H.L. Mencken Award for Investigative Reporting, the Champion of Justice Award for reporting on the drug war, and the John Hancock Award for business reporting. Lynn was also a Knight Medical School Fellow at the University of Michigan.

View all post by Lynn Eisler Visit author's website

Write Your Comment